About Us

Atanse (ah-TAHN-say) enables the treatment of devastating neurological diseases through pioneering intracerebral therapeutic delivery technology. We strive to develop stereotactic instruments that provide neurosurgeons with the highest possible accuracy and precision while minimizing associated trauma. 

Atanse was chosen as the company's name because of one of our founder's history with the Dakota Sioux. Atanse is the Dakota word for "silent" and represents our stealth approach to restorative therapeutic delivery and our respect for the patients we help and for the power of effective neurosurgical intervention. 

Executive Team


Mike Kelly

Chief Executive Officer

Mr. Kelly is an experienced engineer and entrepreneur, having bought and integrated seven companies and sold five. He has a BS/MS from the Massachusetts Institute of Technology and an MBA from Harvard University. 



Miles Cunningham

Chief Scientific Officer

Dr. Cunningham is the Director of the Laboratory for Neural Reconstruction at McLean Hospital and is affiliated with Harvard University Medical School. He has an MD from Harvard University and a PhD from the Massachusetts Institute of Technology. 


Edward Berger

Advisor & Board Member

Dr. Berger is a life sciences industry veteran with over 30 years of experience in regulation and reimbursement. He has a BA from Harvard University and a PhD from Boston University.

Scientific AdvisErs

Alexandra Golby, MD, PhD
Associate Professor of Neurosurgery, Harvard Medical School
Brigham and Women’s Hospital, Boston, Massachusetts

Jeffrey Bruce, MD, PhD
Professor of Neurosurgery, Columbia Presbyterian Hospital, New York

Guido Nikkhah, MD, PhD
Vice Chairman, Dept of Stereotactic and Functional Neurosurgery, University Neurosurgery Clinic, Freiburg, Germany

Jens Christian Sorensen, MD, PhD
Chair, Department of Neurosurgery, Aarhus University Hospital, Denmark

Craig van Horne, MD, PhD
Chair, Department of Neurosurgery, St. Elizabeth’s Hospital, Brighton, Massachusetts